Abstract 35P
Background
Current immune research on soft tissue sarcomas (STS) primarily focuses on analyzing the tumor microenvironment and adjacent lymph nodes. However, alternative methods are necessary to monitor immune responses in non-surgical patients due to limited opportunities to study tumor-infiltrating lymphocytes. This study aimed to assess the peripheral immune profile of STS patients and its impact on patient survival.
Methods
Blood samples were collected from 55 STS patients and age-matched healthy individuals. Flow cytometry and qRT-PCR were conducted on whole blood, to proceed with deep immunophenotyping and gene expression quantification, respectively. Proteomic analysis was also performed on plasma samples by xMAP technology. Unsupervised clustering analysis was used to classify patients based on their immunotype.
Results
Significant differences were found between STS patients and healthy individuals. STS patients showed lymphopenia, particularly affecting B and CD4 T cells, with an expansion of myeloid cells such as granulocytes and monocytic-derived suppressor cells (M-MDSC). Gene expression analysis revealed decreased levels of activatory and cytotoxic-related factors, along with increased expression of ARG1, which may inhibit anti-tumoral activity. A tendency for increased levels of IL-10 and soluble checkpoint inhibitors VISTA and TIMD-4 were also observed in plasma samples. Furthermore, patients were classified into three distinct immunotypes: \"immune-high,\" \"immune-intermediate,\" and \"immune-low.\" These immunotypes correlated significantly with time after collection (TAC), which refers to the time from sample collection to the end of the study or occurrence of a death event. \"Immune-high\" patients had elevated levels of immune-related factors associated with cytotoxic/effector activity and longer TAC, while \"immune-low\" patients had increased levels of immune-related factors associated with inflammation and inhibition, and shorter TAC.
Conclusions
The correlation between immunotypes and survival times emphasizes the importance of studying peripheral blood samples in STS. Evaluating the peripheral immune response can be a valuable tool for monitoring and predicting outcomes in STS patients.
Legal entity responsible for the study
The authors.
Funding
FCT - Portuguese Foundation for Science and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020
Presenter: Geneviève Gueguen Dorbes
Session: Poster Display
148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo
Presenter: Kristel Kemper
Session: Poster Display
149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses
Presenter: anahita rafiei
Session: Poster Display
150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer
Presenter: Eunice Dotse
Session: Poster Display
151P - Tumor organoid-derived TIL therapy for colorectal cancer
Presenter: Marc Leushacke
Session: Poster Display
152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment
Presenter: Nainesh Katagihallimath
Session: Poster Display
153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin
Session: Poster Display
154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer
Presenter: Yi Xu
Session: Poster Display
155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors
Presenter: Hans Prenen
Session: Poster Display
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display